The strong organic growth, improved profitability, and robust 2026 guidance suggest Bioventus is successfully executing its strategy. Traders should monitor the execution of this guidance, particularly the margin expansion and cash flow generation, which could support further stock appreciation.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 5 $9.10entry
- T+1 · 9mo ago −7.58%α −6.27% · $8.41
- T+5 · 8mo ago −5.49%α −3.26% · $8.60
- T+20 · 8mo ago −1.43%α +2.36% · $8.97
- T+60 · 6mo ago −12.86%α −24.16% · $7.93
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Bioventus reported strong Q4 2025 results with $157.9M revenue (2.8% YoY growth, 10% organic growth) and GAAP EPS of $0.21, reversing a prior-year loss. The company achieved $38M in operating cash flow (97% increase) and issued 2026 guidance projecting $600-610M revenue and $0.73-0.77 Adjusted EPS, indicating continued growth momentum.
Key Financial Metrics
Key Facts
- Q4 revenue: $157.9M (+2.8% YoY, +10% organic)
- Q4 GAAP EPS: $0.21 (vs. $0.00 prior year)
- Q4 cash from operations: $38M (+97% YoY)
- 2026 guidance: $600-610M revenue (+6-7%), $0.73-0.77 Adjusted EPS (+7-13%)
- Full-year 2025 revenue: $568.1M (-0.9% YoY, +7.5% organic)
Financial Impact
Q4 revenue increased by $4.3M YoY, with 2026 revenue guidance projecting $32-42M growth over 2025. Adjusted EPS is expected to grow by $0.05-0.09 in 2026.
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Pain Treatments | $79.7M | +15.1% |
| Surgical Solutions | $55.5M | +3.4% |
| Restorative Therapies | $22.7M | -26.0% |
Risk Factors
- The prior-year revenue comparison was affected by the divestiture of the Advanced Rehabilitation Business, which could distort YoY growth metrics.
- The company's Adjusted EPS guidance increase (7-13%) is modest compared to the significant improvement from 2024 to 2025 (from -$0.56 to $0.68).
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001665988-26-000010 |
| Document: bvs-20260305.htm | 0001665988-26-000010 |
| Document: 0001665988-26-000010-index-headers.html | 0001665988-26-000010 |
| Document: 0001665988-26-000010-index.html | 0001665988-26-000010 |
| Document: 0001665988-26-000010.txt | 0001665988-26-000010 |
Track record
18 reports on BVS
2 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +37.19% at T+60 after the May 8, 2026 report. 3 of 6 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $10.66 Now $10.46 −1.88% settles Feb 11
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $10.61 Now $10.46 −1.41% settles Feb 4
- Nov 2, 202614d ago 8-K Neutral 5/10 No price data
- Nov 2, 202614d ago Press Release Neutral 5/10 Entry $10.95 Now $10.46 −4.43% settles Feb 1
- Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $14.65 Now $10.46 −28.60% settles Jan 26
- Aug 15, 202613w ago Institutional Cluster Mixed 5/10 Entry $13.88 to $11.02 Now $10.46 −24.64% ▼ −20.64% −17.88% vs SPY
- Aug 5, 202614w ago 8-K Bullish 7/10 No price data
- Aug 5, 202614w ago Press Release Bullish 7/10 Entry $15.26 to $14.86 Now $10.46 −31.45% ▼ −2.62% −2.81% vs SPY
- Jun 11, 202622w ago Institutional Cluster Bearish 4/10 Entry $8.68 to $14.07 Now $10.46 −20.51% ▼ −62.10% −57.70% vs SPY
- Jun 2, 202623w ago Press Release Bearish 6/10 Entry $8.11 to $13.97 Now $10.46 −28.98% ▼ −72.26% −71.14% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers